Monograph
M05BX03 - Strontium Ranelate |
Not porphyrinogenic |
NP |
Rationale
Strontium ranelate is not metabolised and does not inhibit or induce CYP450 enzymes.
Risk for gastrointestinal adverse events in the form of nausea and diarrhoea motivates vigilance against insufficient intake of food, especially of carbohydrate.
Therapeutic characteristics
Strontium ranelate is indicated for the treatment of osteoporosis.
Common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are nausea, diarrhoea and loose stools.
Metabolism and pharmacokinetics
Stronitum is a divalent cation and is not metabolised. It does not inhibit CYP450 enzymes (SPC).
IPNet drug reports
Uneventful use reported in 2 patients with acute porphyria.
References
| # | Citation details | PMID |
|---|---|---|
| * | Summary of Product Characteristics | |
| 1. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Strontium ranelate.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Belgium
United Kingdom
Denmark
Luxembourg© NAPOS 2024